Evotec SE
EVO Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$1.57
KIRA · Stoqly’s AI analyst, in plain words
- Evotec SE had $889M of revenue in fiscal 2025, up 3.1% on the year before. Over five years, revenue changed +9.3% a year on average.
- Its operating margin was −7.1%, up 10.8 pts: of every 100 in sales, about −7 is left after running the business.
- Evotec SE lost $117M in fiscal 2025.
- Free cash flow was −$92.2M in fiscal 2025, −10.4% of revenue.
- Evotec SE returned $1.7M to shareholders in fiscal 2025. The diluted share count rose 0.2%.
- Evotec SE has $167M more cash than debt.
Market cap
$558M
P/E
—
Revenue
$889M
Net income
−$117M
Free cash flow
−$92.2M
Operating margin
−7.1%
Evotec SE in 30 seconds · fiscal 2025
Are sales growing?
+3.1%
Only a little. Sales grew 3.1% last year.
Does it make a profit?
−13.1%
No. It lost money last year.
Does profit turn into cash?
−10.4%
No. It spent more cash than it brought in.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
5 / 9
Mixed. It passes 5 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Evotec SE does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Apr 8, 2026
- Legal name
- Evotec SE
- CIK
- 0001412558
Evotec SE · EVO
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $731M | $790M | $845M | $862M | $889M |
| Revenue growth | 28.0% | 8.1% | 7.0% | 2.0% | 3.1% |
| Gross margin | 24.5% | 23.2% | 22.4% | 14.4% | 14.5% |
| Operating margin | 6.6% | 2.8% | −6.1% | −17.9% | −7.1% |
| Net income | $255M | −$185M | −$90.7M | −$212M | −$117M |
| Net margin | 34.9% | −23.4% | −10.7% | −24.6% | −13.1% |
| Diluted EPS | $0.77 | −$0.52 | −$0.25 | −$0.60 | −$0.33 |
| Cash | |||||
| Cash from operations | $150M | $216M | $39.4M | $19.7M | −$10.4M |
| Capital expenditure | $141M | $191M | $231M | $127M | $81.8M |
| Free cash flow | $9.1M | $25.7M | −$191M | −$107M | −$92.2M |
| FCF margin | 1.2% | 3.3% | −22.6% | −12.5% | −10.4% |
| Share buybacks | — | — | — | — | $1.7M |
| Share count change | 8.2% | 6.2% | 0.1% | 0.2% | 0.2% |
| Debt and strength | |||||
| Cash and short-term investments | $792M | $443M | $565M | $318M | $492M |
| Debt incl. finance leases | $411M | $352M | $483M | $299M | $325M |
| Shareholders' equity | $1.6B | $1.3B | $1.2B | $990M | $956M |
| Net debt / EBITDA | −2.9x | −0.8x | −1.7x | — | −3.4x |
| Current ratio | 3.4x | 3.2x | 1.9x | 2.0x | 2.1x |
| Interest coverage | 4.4x | 1.6x | — | — | — |
| Returns and quality | |||||
| Return on capital | 3.7% | 1.5% | −3.5% | −12.6% | −6.3% |
| Return on equity | 20.8% | −13.1% | −7.2% | −19.0% | −12.0% |
| Return on tangible equity | 20.7% | −19.5% | −9.9% | −31.7% | −19.5% |
| Piotroski F-score | 5 | 4 | 4 | 5 | 5 |
| Altman Z'' | 3.8 | 2.8 | 1.5 | 0.5 | 0.8 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Evotec SE · EVO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.57 a share, the company is worth $558M.
Source: SEC EDGAR XBRL filings (CIK 0001412558). Data updated October 24, 2026. Filed in EUR under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only — not investment advice. Check the original filings before relying on any figure.